PTIXW | Protagenic Therapeutics, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	0.0090 - 0.0090
52 Week Range	0.0090 - 0.0090
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	400
Average Volume	N/A
Shares Outstanding	306,752,555
Market Cap	4,199,641
Sector	Healthcare
Industry	Biotechnology
IPO Date	2021-04-27

Valuation
Profitability
Growth
Health
P/E Ratio	N/A
Forward P/E Ratio	N/A
EPS	N/A
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	1
Country	USA
Website	PTIXW

Protagenic Therapeutics, Inc., a pre-clinical biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound, PT00114 is a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. The company was founded in 2016 and is based in New York, New York.

PTIXW's peers: ACXP, APRE, GFAIW, LUMO, TCBPW

*Chart delayed

Analyzing fundamentals for PTIXW we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see PTIXW Fundamentals page.

Watching at PTIXW technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on PTIXW Technicals page.